Group 1 - The article announces the public solicitation for sub-fund management institutions to collaborate with the Ningbo Strategic Emerging Industry Investment Fund, aiming to promote the integration of technological and industrial innovation through capital support for strategic emerging industries [3][4]. - The Ningbo Strategic Emerging Industry Investment Fund is established by the Ningbo municipal government, operating under principles of government guidance, market operation, scientific decision-making, and risk prevention, focusing on major strategies, key areas, and weak links [4]. Group 2 - Sub-fund management institutions must meet regulatory requirements and be registered with the Asset Management Association of China [6]. - The registered capital of the sub-fund management institution must be no less than 10 million yuan, with a cumulative fund management scale or external equity investment scale of at least 300 million yuan [7]. - The management team should consist of at least three senior managers with over three years of experience in equity investment or related fields [8]. Group 3 - The sub-fund management institution should have at least three successful equity investment cases, where each case yields a total return of no less than 20% or a fair value return of over 50% [10]. - A sound equity investment management and risk control system must be in place, along with a compliant operational history for the last three years [11][12]. Group 4 - The institution should demonstrate strong fundraising capabilities, with a commitment from potential investors generally not less than 30% of the sub-fund's subscribed scale [13]. - The institution or its affiliates must commit to contributing at least 1% of the total subscribed capital of the sub-fund, with specific thresholds for larger funds [14]. Group 5 - Institutions can self-evaluate their eligibility and obtain the application guidelines by sending their introduction materials to the designated email [16][17]. - The application period is open until April 17, 2026, with the possibility of early closure depending on the number of applications received [21].

Core Viewpoint - Shanghai Yangquan Private Fund Management Co., Ltd. is publicly selecting sub-fund management institutions to collaborate with its parent fund, the Yangquan High-tech Industry Development Guidance Venture Capital Fund Partnership (Limited Partnership) [1][3]. Group 1: Sub-fund Types and Investment Focus - The sub-funds will focus on the investment scope and requirements of the parent fund, with specific types including: - New Energy and New Materials Industry Fund, targeting key enterprises in lithium batteries, sodium batteries, and energy storage applications to promote deep integration and development of the new energy battery industry [1]. - Strategic Emerging Industry Fund, investing in high-quality enterprises in sectors such as information technology, semiconductors, big data, optoelectronics, photovoltaics, carbon-based new materials, special metal materials, bio-based new materials, advanced rail transit equipment, intelligent manufacturing equipment, smart connected new energy vehicles, general aviation, modern biomedicine, and environmental protection [2]. Group 2: Fund Structure and Investment Limits - The sub-fund organization must adopt a limited partnership or corporate structure, with a duration not exceeding the remaining duration of the parent fund. The parent fund's investment in a single enterprise or specific sub-fund cannot exceed 20% of the parent fund's subscribed scale and must not exceed 20% of the total assets of the parent fund throughout its lifecycle. Additionally, the parent fund's investment in other sub-funds cannot exceed 50% of the subscribed scale of those sub-funds [2]. Group 3: Parent Fund Details - The parent fund, Yangquan High-tech Industry Development Guidance Venture Capital Fund Partnership (Limited Partnership), has a total scale of 3 billion and 1 million (30.01 billion) yuan, established in July 2024, with a duration of 10 years. It focuses on investing in key industries that align with the development needs of the Yangquan High-tech Zone, supporting the 14 strategic emerging industries outlined in the Shanxi Provincial Government's "14th Five-Year Plan" [3].

Core Viewpoint - The company, Wenkexin (002775.SZ), is advancing its strategic transformation by partnering with Foshan Jianfa and Jianfa Fund to establish the Foshan Jianfa Pioneer Industry Investment Partnership, with a total subscription amount of 500 million yuan [1] Group 1: Partnership Details - The company will contribute 29 million yuan, representing 5.80% of the total subscription amount [1] - Jianfa Fund will act as the general partner and manager, contributing 1 million yuan, which is 0.20% of the total [1] - Foshan Jianfa is the main limited partner, contributing 470 million yuan, accounting for 94.00% of the total [1] Group 2: Investment Focus - The partnership will focus on strategic emerging industries prioritized by the state, including new energy, new materials, next-generation information technology, and advanced manufacturing [1] - Investment scope includes equity in unlisted companies, shares in limited partnerships, and non-public offerings of listed companies [1]

Group 1 - The company plans to increase capital by 260 million yuan to the investment management company and 252 million yuan to the Su Xin Equity Fund, with the investment management company contributing 249.48 million yuan and the private fund company contributing 2.52 million yuan [3][8] - The board of directors approved the investment proposal with a unanimous vote of 9 in favor [4] - The transaction does not require shareholder meeting approval and is not classified as a related party transaction or a major asset restructuring [5][6] Group 2 - The investment management company, established in 2017, has set up 9 industry investment funds with a total subscribed capital of 1.264 billion yuan, leveraging a total fund size of 9.109 billion yuan [7] - The Su Xin Equity Fund has a registered capital of 248 million yuan and focuses on strategic emerging industries such as high-end equipment manufacturing and new materials, achieving a 14.81% appreciation by the end of 2024 [7][9] - The investment management company’s equity as of December 31, 2024, was approximately 1.4 billion yuan, with a net asset value per unit of 1.3647 yuan [9] Group 3 - The external investment aims to expand the company's industrial investment scale, increase investment in quality projects, and enhance investment returns [10]

Core Viewpoint - The company, Huayi Family Co., Ltd., is investing approximately RMB 299.99 million to subscribe for 63,157,894 new shares of Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. at a price of RMB 4.75 per share, constituting a related party transaction [1][2][6]. Group 1: Transaction Overview - The company signed a subscription agreement on August 10, 2025, to participate in Haihe Pharmaceutical's share issuance, with a total investment not exceeding RMB 300 million [2]. - The company will hold at least 5% of Haihe Pharmaceutical's total shares after the financing is completed [2]. - The company completed the payment of RMB 299,999,996.50 on September 25, 2025, and Haihe Pharmaceutical will proceed with the necessary registration changes [4]. Group 2: Governance and Rights - The company has the right to nominate one observer to the board of Haihe Pharmaceutical, who can attend meetings and provide opinions but does not have voting rights [3]. - The agreement will take effect once all parties have affixed their official seals [3]. Group 3: Strategic Purpose and Impact - The investment aligns with the company's strategy to enhance its core competitiveness and profitability while exploring opportunities in emerging industries [7]. - This strategic financial investment is based on the long-term potential of innovative drugs, aiming to ensure stable operations of the main business while obtaining reasonable financial returns [7]. - The company's financial structure is stable, with a low debt-to-asset ratio, indicating that this investment will not adversely affect its financial and operational status [7].

Core Viewpoint - Zhaoyan New Drug (603127.SH) is establishing a seed fund in collaboration with investment management firms to focus on strategic emerging industries, particularly in biomedicine and high-end medical devices [1] Group 1 - The company plans to sign a partnership agreement with Yifeng Capital and Yifeng Mingyuan Technology to set up the Shenzhen Yifeng Guangming Science City Seed Fund [1] - The fund will target investments in industries supported by the Shenzhen government, emphasizing biomedicine and high-end medical devices [1] - The company or its designated subsidiary will contribute no more than 10 million RMB as a limited partner in the fund [1]

Core Viewpoint - The company plans to invest up to RMB 300 million in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share subscription, aiming to hold at least 5% of the company's equity post-financing [1][3][27] Group 1: Transaction Overview - The share subscription price is set at RMB 4.75 per share, with a maximum subscription of 63.157895 million shares [1][3] - The financing plan involves a rights issue where existing shareholders can subscribe for new shares at a ratio of 2 shares for every 10 shares held [2][19] - The transaction constitutes a related party transaction due to the company's relationship with the controlling shareholder, Shanghai Nanjing Group [1][4] Group 2: Financial and Valuation Aspects - The estimated value of Haihe Pharmaceutical's total equity ranges from RMB 3.41 billion to RMB 4.01 billion based on asset-based valuation methods [20][21] - The company has a solid financial structure, with a low debt-to-asset ratio, indicating that the investment will not adversely affect its financial status [27] Group 3: Business and Market Context - Haihe Pharmaceutical focuses on innovative drug development in the oncology sector, with several products already commercialized or in advanced clinical stages [11][12] - The biopharmaceutical industry is a key growth area in Shanghai, supported by favorable policies and significant market potential [26][27] - The company has established a comprehensive R&D system and has multiple drug pipelines, indicating strong innovation capabilities [12][15]

Core Viewpoint - Sichuan Borui Rongben Equity Investment Partnership (Limited Partnership) is actively seeking to recruit sub-fund management institutions to promote investment in strategic emerging industries in Ya'an City and Yucheng District, with the aim of supporting the incubation, cultivation, and development of technology-based enterprises in the region [1][2]. Group 1 - The total scale of the Borui Rongben Fund is 700 million RMB, focusing on supporting early, mid, and growth-stage technology enterprises through the establishment of sub-funds and equity investments [1][2]. - The sub-funds are expected to be registered in Yucheng District, Ya'an City, and must comply with national regulations for registration and supervision [1]. - The mother fund's contribution to any single sub-fund will not exceed 50% of the sub-fund's total scale, and investments in a single sub-fund will not exceed 20% of the mother fund's total committed capital [2]. Group 2 - The investment focus of the fund includes strategic emerging industries such as high-end equipment manufacturing, new materials, and new energy, providing strong support for the incubation and development of technology-based enterprises in Ya'an City and Yucheng District [2].

Core Viewpoint - The establishment of a 1 billion yuan investment fund by companies under China Resources, in collaboration with Shanghai Fosun Pharmaceutical and Chengdu state-owned enterprises, aims to focus on the pharmaceutical and health sectors, particularly in innovative drug development and strategic emerging industries [2][4]. Group 1: Fund Structure and Partners - The fund, named China Resources Pharmaceutical (Chengdu) Innovation Investment Fund, has a total capital of 100 million yuan, with various partners contributing different amounts [3]. - The general partner (GP) is China Resources Pharmaceutical (Chengdu) Enterprise Management Partnership (Limited Partnership), while limited partners (LPs) include several pharmaceutical companies and investment funds [2][3]. - The fund's lifespan is set for 7 years, with a 3-year investment period and a 4-year exit period, extendable by 1 year upon partner approval [3]. Group 2: Investment Focus - The fund will concentrate on the pharmaceutical health sector and strategic emerging industries, targeting areas such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices, and traditional Chinese medicine [4]. - The involvement of the Chengdu Bio-City Jingchuang Equity Investment Fund indicates a strong potential for project implementation within the Chengdu Tianfu International Bio-City [4]. Group 3: Historical Context - An earlier fund, the China Resources Pharmaceutical (Shantou) Industry Investment Fund, was established 8 years ago but did not perform as expected, failing to reach its initial target of 2.5 billion yuan [4][6]. - The Shantou fund entered a liquidation phase in December 2024, having not achieved the anticipated scale, which affected the contributions of its partners [5][6].